

NCT ID	NCT03921684
Title	Trial of Nivolumab With FOLFOX After Chemoradiation in Rectal Cancer Patients
Phase	Phase 2
Date Added	2019-04-19
Location	Israel
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	capecitabine, mFOLFOX6, Nivolumab
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT02675946
Title	CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)
Phase	Phase 1
Date Added	2016-02-05
Location	California, United States Colorado, United States Connecticut, United States District of Columbia, United States Florida, United States Georgia, United States Hawaii, United States Illinois, United States Indiana, United States Maryland, United States Massachusetts, United States Nebraska, United States New Jersey, United States North Carolina, United States Pennsylvania, United States South Dakota, United States Tennessee, United States Texas, United States Washington, United States Wisconsin, United States Taiwan
Prior IO Allowed	No
CRC-directed	No
Status	Recruiting
Drugs	cetuximab, CGX1321, encorafenib, Pembrolizumab, Keytruda
Tags	MSS/ MMRp
NCT ID	NCT03566355
Title	Curative Proton Beam Therapy for Patients With Lung Metastasis of Colorectal Cancer
Phase	Not Applicable
Date Added	2018-06-25
Location	Korea, Republic of
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT03608046

Title	Avelumab Combined With Cetuximab and Irinotecan for Treatment Refractory Metastatic Colorectal Microsatellite Stable Cancer
Phase	Phase 2
Date Added	2018-07-31
Location	Belgium
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	Avelumab, Cetuximab Injection, Irinotecan
Tags	MSS/ MMRp
NCT ID	NCT03638206
Title	Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
Phase	Phase 1/Phase 2
Date Added	2018-08-20
Location	China
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	CAR-T cell immunotherapy
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT03740256
Title	Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors
Phase	Phase 1
Date Added	2018-11-14
Location	Texas, United States
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	CAdVEC
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT03772561
Title	Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies
Phase	Phase 1
Date Added	2018-12-11
Location	Singapore
Prior IO Allowed	No
CRC-directed	No
Status	Recruiting
Drugs	AZD5363+Olaparib+Durvalumab
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	PG545 (pixatimod) in combination with nivolumab
Title	PG545 (pixatimod) in combination with nivolumab
Phase	Phase 1
Date Added	2019-04-26
Location	
Prior IO Allowed	Yes

CRC-directed	Yes
Status	Recruiting
Drugs	
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT04626635
Title	REGN7075 in Combination With Cemiplimab in Adult Participants With Advanced Solid Tumors
Phase	Phase 1, Phase 2
Date Added	2020-11-12
Location	California, United States Colorado, United States Florida, United States Illinois, United States Iowa, United States Massachusetts, United States Michigan, United States New Jersey, United States New York, United States Ohio, United States Pennsylvania, United States Tennessee, United States Texas, United States Washington, United States Wisconsin, United States France Israel Netherlands Poland Spain Turkey (Türkiye)
Prior IO Allowed	Yes
CRC-directed	No
Status	Recruiting
Drugs	cemiplimab, REGN7075
Tags	MSS/ MMRp
NCT ID	NCT04991948
Title	Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer
Phase	Phase 1
Date Added	2021-08-05
Location	Florida, United States Belgium
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	CYAD-101, FOLFOX, Pembrolizumab
Tags	MSI-H/ MMRd, MSS/ MMRp